September 12 2019
Results from twenty-one NRG Oncology clinical trials will be presented at the 2019 American Society for Radiation Oncology (ASTRO) Annual Meeting in Chicago, Illinois this September. All four ASTRO Plenary Session presentations are featuring NRG Oncology research, and these four highly impactful projects were chosen from over 3,000 submitted abstracts. The NRG Oncology presentations at the meeting will include results from trials for patients with brain tumors, spine metastases, or anal, breast, cervix, genitourinary, gynecologic, head and neck, liver, lung, or prostate cancer.
“For the first time ever, all four ASTRO Plenary Session presentations will feature NRG Oncology research. This work and the seventeen other NRG Oncology abstracts being presented at ASTRO are a testament to the creativity and dedication of our partners, investigators, trial participants, clinical research staff members, and all persons involved in NRG Oncology trials. We are incredibly thankful for all the efforts that have gone into making this work possible,” stated Walter J. Curran, Jr., MD, FACR, FASCO, an NRG Oncology Group Chairman and the Executive Director of the Winship Cancer Institute of Emory University.
The featured NRG Oncology researchers and topics at the ASTRO Plenary Session are:
- Sue Yom, MD, PhD, of the University of California at San Francisco and the lead author of the NRG-HN002 abstract will present on the progression-free survival and swallowing-related quality of life results of the randomized phase II trial, which studied reduced-dose intensity-modulated radiotherapy with cisplatin for patients with oropharyngeal cancer.
- Julia R. White, MD, of the Ohio State University Comprehensive Cancer Center and the lead author of the NRG-NSABP B-39/RTOG 0413 abstract will present the quality of life substudy results of this phase III trial comparing whole breast irradiation to partial breast irradiation for women with early stage breast cancer.
- Samuel Ryu, MD, of the Stony Brook University Medical Center and lead author of NRG-RTOG 0631 abstract will present on the pain response results of this trial that compared stereotactic body radiotherapy or radiosurgery to conventional external beam radiotherapy for patients with spine metastases.
- Daniel Spratt, MD, of the University of Michigan and lead author of the secondary analysis of NRG-RTOG 9601 abstract will present on the addition of hormone therapy to early salvage radiotherapy for men with biochemically recurrent prostate cancer.
The full schedule of NRG Oncology clinical research presentations at ASTRO 2019 can be found here on the organization’s website
About NRG Oncology
NRG Oncology conducts practice-changing, multi-institutional clinical and translational research to improve the lives of patients with cancer. Founded in 2012, NRG Oncology is a Pennsylvania-based nonprofit corporation that integrates the research of the legacy National Surgical Adjuvant Breast and Bowel Project (NSABP), Radiation Therapy Oncology Group (RTOG), and Gynecologic Oncology Group (GOG) programs. The research network seeks to carry out clinical trials with emphases on gender-specific malignancies, including gynecologic, breast, and prostate cancers, and on localized or locally advanced cancers of all types. NRG Oncology’s extensive research organization comprises multidisciplinary investigators, including medical oncologists, radiation oncologists, surgeons, physicists, pathologists, and statisticians, and encompasses more than 1,300 research sites located world-wide with predominance in the United States and Canada. NRG Oncology is supported primarily through grants from the National Cancer Institute (NCI) and is one of five research groups in the NCI’s National Clinical Trials Network.